VSTM News and Press, Verastem Inc. From 05/24/24

2024-05-24 11:30:00 ET Verastem Inc (NASDAQ: VSTM) opened nearly 70% down this morning even though the pharmaceutical firm reported positive interim data for its combination therapy as a treatment of pancreatic cancer. Here’s what is hitting $VSTM today The oncology compa...

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...

2024-05-24 08:28:58 ET More on Verastem Verastem stock rallies on positive data for pancreatic cancer drug combo Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy Seeking Alpha’s Quant Rating on Verastem Historical earnings data...

2024-05-24 08:16:00 ET More on pre-market losers & stocks. RenovaroCube to acquire 100% ownership of Cyclomics Financial information for Ainos Financial information for Binah Capital Group, Inc. Financial information for Renovaro Inc. Compare metr...

Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan to present the mature dataset from RAMP 201 at a medical conference in the second half of 2024 Avutometinib and defactinib combination h...

2024-05-23 18:14:04 ET More on Verastem Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial information for Verastem Read the full ...

83% (5/6) of patients achieved a confirmed partial response in cohort 1, the most mature dose level; one dose-limiting toxicity was observed, however, the dose level was subsequently cleared after additional patients were enrolled Follow up of patients in the additional dose and schedule ...

2024-05-18 20:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-09 17:23:46 ET More on Verastem Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial information for Verastem Read the full ...

Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer in Q2 2024 FDA Fast Track Designation granted for avutometinib in combination with adagrasib for the treatment o...